Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Lifecycle of Erythrocytes01:22

Lifecycle of Erythrocytes

Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Qualified prediction system for allograft failure in real world settings: extended validation study.

BMJ medicine·2026
Same author

Long-Term Outcome of Kidney Transplant Patients from Rural Farming Areas with Balkan Nephropathy-A Single-Centre Report.

Journal of clinical medicine·2026
Same author

Post-Transplant Sepsis After Liver Transplantation: Clinical Characteristics and Therapeutic Challenges.

Journal of clinical medicine·2026
Same author

Uremic Pruritus in Hemodialysis: Mechanisms, Burden, and Emerging Therapies.

Journal of clinical medicine·2026
Same author

Exploring Perspectives on Kidney Donation: Medical and Non-Medical Students in Croatia.

Journal of clinical medicine·2026
Same author

Oral Nutritional Supplement Adherence and Nutritional Outcomes in Hemodialysis Patients-A Prospective Study.

Journal of clinical medicine·2025

Related Experiment Video

Updated: May 24, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

[Post-transplant erythrocytosis].

Zeljka Mustapić1, Nikolina Basić-Jukić, Vesna Lovcić

  • 1Klinicki bolnicki centar Zagreb i Medicinski fakultet Sveucilista u Zagrebu, Zavod za nefrologiju, arterijsku hipertenziju i dijalizu, Hrvatska. zpalekal@hotmail.com

Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti
|February 25, 2012
PubMed
Summary

Post-transplant erythrocytosis, a common complication after kidney transplants, can lead to hyperviscosity symptoms. Renin-angiotensin system (RAS) inhibitors effectively lower hematocrit and reduce fatal risks.

More Related Videos

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
14:22

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Related Experiment Videos

Last Updated: May 24, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
14:22

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Area of Science:

  • Nephrology
  • Hematology
  • Transplantation Medicine

Context:

  • Post-transplant erythrocytosis (PTE) affects 10%-15% of renal transplant recipients.
  • Typically occurs 8-24 months post-transplantation.
  • Characterized by hematocrit >55%, leading to hyperviscosity syndrome in 75% of cases.

Purpose:

  • To summarize the etiology and management of post-transplant erythrocytosis.
  • To highlight the efficacy of renin-angiotensin system (RAS) inhibition in treating PTE.

Summary:

  • PTE etiology is multifactorial, involving erythropoietin, RAS, and IGF-1.
  • RAS inhibition, using ACE inhibitors or ARBs, is a highly effective therapy for PTE.
  • Treatment leads to hematocrit reduction in 90% of patients within 2-6 weeks.

Impact:

  • RAS inhibition significantly decreases the incidence of fatal complications such as pulmonary embolism and stroke.
  • Effective management of PTE improves patient outcomes and reduces long-term risks post-renal transplantation.